Use of different buffers in peritoneal dialysis

被引:16
|
作者
Feriani, M [1 ]
机构
[1] Umberto 1 Hosp, Dept Nephrol, I-30174 Mestre Venice, Italy
关键词
D O I
10.1046/j.1525-139x.2000.00069.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A buffer is included in the peritoneal dialysis solution in order to offset the hydrogen ions normally produced during the metabolic processes. Nowadays, the buffer used is lactate, and its concentration in conventional peritoneal dialysis fluids is 35 or 40 mmol/L. Despite the general thought that peritoneal dialysis adequately corrects uremic acidosis, several studies have demonstrated that more than 50% of patients present mild to moderate acidosis with the solution containing 35 mmol/L of lactate, although with a 40 mmol/L solution this percentage decreases, a substantial number of patients still remain acidotic. This acid-base derangement is characterized by a normal pH and a below-normal plasma bicarbonate concentration, although the external body base balance is in equilibrium. There is evidence that this condition contributes to uremic osteodystrophy and has a detrimental effect on protein metabolism. Conventional solutions also affect mesothelial cell viability and local leukocyte function and have potential systemic effects such as the impairment of cellular redox state. New solutions containing pure bicarbonate or a mixture of bicarbonate and lactate have recently been investigated. A bicarbonate solution containing 34 mmol/L significantly increased plasma bicarbonate levels as compared with the lactate 35 mmol/L solution. It has been demonstrated that bicarbonate solutions have better biocompatibility than the lactate buffered solution and substantially reduce abdominal discomfort experienced by a certain percentage of patients during the solution infusion. These studies demonstrated that the bicarbonate-buffered CAPD solution is safe, well-tolerated, and does not present any, even potential, side effects. Thus, it seems reasonable to consider the bicarbonate buffered solution the standard instead of the alternative, and it might entirely replace lactate as buffer in peritoneal dialysis fluid.
引用
收藏
页码:256 / 260
页数:5
相关论文
共 50 条
  • [41] USE OF PERITONEAL DIALYSIS IN EXPERIMENTAL AMPHETAMINE POISONING
    ZALIS, EG
    COHEN, RJ
    LUNDBERG, GD
    PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1965, 120 (02): : 278 - &
  • [42] Icodextrin - A review of its use in peritoneal dialysis
    Frampton, JE
    Plosker, GL
    DRUGS, 2003, 63 (19) : 2079 - 2105
  • [43] In Reply to "The Use of Ultrasound in Peritoneal Dialysis Setting"
    Niyyar, Vandana Dua
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 84 (06) : 798 - 799
  • [44] OPTIMAL USE OF PERITONEAL DIALYSIS IN PATIENTS WITH DIABETES
    Chung, Sung Hee
    Noh, Hyunjin
    Ha, Hunjoo
    Lee, Hi Bahl
    PERITONEAL DIALYSIS INTERNATIONAL, 2009, 29 : S132 - S134
  • [45] Use of MiDialisis App in peritoneal dialysis patients
    Frias-Gonzalez, Aida
    Gonzalez-Bermudez, Ana
    Caro, Jara
    Bergesio, Luca
    Ruiz, Enrique Morales
    Bernardos, Ana Maria
    Yuste, Claudia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [46] Use of amino acids in peritoneal dialysis solutions
    Bruno, M
    Gabella, P
    Ramello, A
    PERITONEAL DIALYSIS INTERNATIONAL, 2000, 20 : S166 - S171
  • [47] Use of new peritoneal dialysis solutions in children
    Canepa, A.
    Verrina, E.
    Perfumo, F.
    KIDNEY INTERNATIONAL, 2008, 73 : S137 - S144
  • [48] Is It Safe? A Case of Apixaban Use in Peritoneal Dialysis
    Jiwani, R.
    Faiz, F.
    Moey, M.
    Jain, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [49] Is It Safe? A Case of Apixaban Use in Peritoneal Dialysis
    Jiwani, Rahim A.
    Faiz, Fardeen A.
    Mao, Yuxuan
    Moey, Melissa
    Bradner, Evan D.
    Badwan, Wafa R.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2022, 363 (02): : 199 - 201
  • [50] USE OF PERITONEAL DIALYSIS IN CONGESTIVE HEART FAILURE
    PEARL, MA
    MCCRACKEN, BH
    WESTFALL, R
    RAPPAPORT, M
    DISEASES OF THE CHEST, 1964, 46 (03): : 377 - 377